FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2169362062> ?p ?o ?g. }

• W2169362062 endingPage "1555" @default.
• W2169362062 startingPage "1551" @default.
• W2169362062 abstract "Most patients with myelodysplastic syndrome (MDS) are classified at diagnosis as having a low/INT-I or INT-II/high risk disease, based on the classical International Prognostic Scoring System (IPSS) criteria. The low/INT-I risk patients are usually managed mildly with supportive care, including red blood cell (RBC) transfusions, erythroid stimulating agents (ESAs), other cytokines (G-CSF, platelet stimulating agents), as well as thalidomide and lenalidomide. Some patients receive immunosuppressive therapy, and iron chelation is indicated in iron overloaded patients. Aggressive approach (hypomethylating agents, chemotherapy and stem cell transplantation) is usually not applied in such patients. Occasionally, we observe a “low risk” patient with rapid progression of disease and poor outcome. Can we identify demographic, clinical, laboratory, cellular-biological and/or molecular parameters that can predict “poor prognostic features” (PPF) in “low risk” MDS patients? Clinical and laboratory parameters have been reported to be associated with poor prognosis, in addition to the known “classical” IPSS criteria. These include older age, male gender, poor performance status, co-morbidities, degree of anemia, low absolute neutrophile count (ANC) and platelet counts, RBC transfusion requirements, high serum ferritin, high LDH, bone marrow (BM) fibrosis, increased number of BM CD34+ cells and multi-lineage dysplasia. Certain immunophenotypes (low CD11b, high HLA-Dr, CD34, CD13 and CD45), clonal granulocytes, multiple chromosomal abnormalities, chromosomal instability, short telomeres and high telomerase activity were also reported as PPF. Studies of apoptosis identified Bcl-2 expression and high caspase 3 as PPF, while the reports on survivin expression have been confusing. Recent exciting data suggest that methylation of p15 INK4b and of CTNNA1 (in 5q−), high level of methylation of other genes, absence of the TET2 mutation, down regulation of the lymphoid enhancer binding factor 1 (LEF1), mutation of the polycomb-associated gene ASXL1 and a specific 6-gene signature in gene expression profiling – are all associated with poor prognosis in MDS. Do we have data suggesting a different treatment for “low risk” MDS patients displaying PPF? Two teams, the combined Nordic-Italian and the GFM groups have reported an improved survival with ESAs. The GFM has achieved prolonged survival with iron chelation. Recently, encouraging data with survival advantage in azacitidine-treated patients have been published, including a few INT-I patients. Finally, data suggest that low/INT-I MDS patients who undergo stem cell transplantation (SCT0 do better than INT-II/high risk patients). In summary, some patients, classified as “low risk MDS” carry PPF. An appropriate therapeutic approach is indicated. Future updated classifications and prospective trials may lead to a better outcome." @default.
• W2169362062 created "2016-06-24" @default.
• W2169362062 creator A5029981922 @default.
• W2169362062 creator A5048794053 @default.
• W2169362062 creator A5056694098 @default.
• W2169362062 creator A5068365661 @default.
• W2169362062 date "2010-12-01" @default.
• W2169362062 modified "2023-09-26" @default.
• W2169362062 title "The lower risk MDS patient at risk of rapid progression" @default.
• W2169362062 cites W1711791220 @default.
• W2169362062 cites W187238933 @default.
• W2169362062 cites W1885881044 @default.
• W2169362062 cites W1955065682 @default.
• W2169362062 cites W1967978314 @default.
• W2169362062 cites W1977305806 @default.
• W2169362062 cites W1978522934 @default.
• W2169362062 cites W1985424121 @default.
• W2169362062 cites W1993484356 @default.
• W2169362062 cites W1996887331 @default.
• W2169362062 cites W1998598673 @default.
• W2169362062 cites W1998920318 @default.
• W2169362062 cites W1999755132 @default.
• W2169362062 cites W2003304924 @default.
• W2169362062 cites W2004089260 @default.
• W2169362062 cites W2005786502 @default.
• W2169362062 cites W2008103792 @default.
• W2169362062 cites W2008586482 @default.
• W2169362062 cites W2010587952 @default.
• W2169362062 cites W2015809796 @default.
• W2169362062 cites W2015900838 @default.
• W2169362062 cites W2020385828 @default.
• W2169362062 cites W2021333892 @default.
• W2169362062 cites W2021588616 @default.
• W2169362062 cites W2024265050 @default.
• W2169362062 cites W2026898144 @default.
• W2169362062 cites W2028827702 @default.
• W2169362062 cites W2029595590 @default.
• W2169362062 cites W2036730592 @default.
• W2169362062 cites W2041053820 @default.
• W2169362062 cites W2052822682 @default.
• W2169362062 cites W2063823548 @default.
• W2169362062 cites W2064930908 @default.
• W2169362062 cites W2067862448 @default.
• W2169362062 cites W2074950804 @default.
• W2169362062 cites W2083450850 @default.
• W2169362062 cites W2083455895 @default.
• W2169362062 cites W2089100617 @default.
• W2169362062 cites W2094676835 @default.
• W2169362062 cites W2102899429 @default.
• W2169362062 cites W2103336749 @default.
• W2169362062 cites W2106428050 @default.
• W2169362062 cites W2114492363 @default.
• W2169362062 cites W2115951040 @default.
• W2169362062 cites W2117327010 @default.
• W2169362062 cites W2118771330 @default.
• W2169362062 cites W2129975746 @default.
• W2169362062 cites W2132469484 @default.
• W2169362062 cites W2138343003 @default.
• W2169362062 cites W2138523107 @default.
• W2169362062 cites W2139087503 @default.
• W2169362062 cites W2141147469 @default.
• W2169362062 cites W2148968593 @default.
• W2169362062 cites W2149982846 @default.
• W2169362062 cites W2154892077 @default.
• W2169362062 cites W2160614656 @default.
• W2169362062 cites W2163583950 @default.
• W2169362062 cites W2164426492 @default.
• W2169362062 cites W2165036959 @default.
• W2169362062 cites W2166506757 @default.
• W2169362062 cites W2166804558 @default.
• W2169362062 cites W2210620858 @default.
• W2169362062 cites W2296225964 @default.
• W2169362062 cites W2404328587 @default.
• W2169362062 cites W2590535600 @default.
• W2169362062 cites W4232645703 @default.
• W2169362062 cites W4253916874 @default.
• W2169362062 doi "https://doi.org/10.1016/j.leukres.2010.05.023" @default.
• W2169362062 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20573398" @default.
• W2169362062 hasPublicationYear "2010" @default.
• W2169362062 type Work @default.
• W2169362062 sameAs 2169362062 @default.
• W2169362062 citedByCount "39" @default.
• W2169362062 countsByYear W21693620622012 @default.
• W2169362062 countsByYear W21693620622013 @default.
• W2169362062 countsByYear W21693620622014 @default.
• W2169362062 countsByYear W21693620622015 @default.
• W2169362062 countsByYear W21693620622016 @default.
• W2169362062 countsByYear W21693620622017 @default.
• W2169362062 countsByYear W21693620622018 @default.
• W2169362062 countsByYear W21693620622019 @default.
• W2169362062 countsByYear W21693620622020 @default.
• W2169362062 countsByYear W21693620622021 @default.
• W2169362062 countsByYear W21693620622022 @default.
• W2169362062 countsByYear W21693620622023 @default.
• W2169362062 crossrefType "journal-article" @default.
• W2169362062 hasAuthorship W2169362062A5029981922 @default.
• W2169362062 hasAuthorship W2169362062A5048794053 @default.
• W2169362062 hasAuthorship W2169362062A5056694098 @default.

• next